In the new era of multiple myeloma we have many opportunities and I think that this is particularly important because the patient can be part of the shared decision making and I think that the idea of having a possibility of administration that is really fast, really safe and really comfortable can be something that the patient should know in order to decide and in order to participate in the decision of the treatment...
In the new era of multiple myeloma we have many opportunities and I think that this is particularly important because the patient can be part of the shared decision making and I think that the idea of having a possibility of administration that is really fast, really safe and really comfortable can be something that the patient should know in order to decide and in order to participate in the decision of the treatment. I think that this comes from IRAKLIA and IZALCO but can potentially can be applied to all these isatuximab-based regimens, and I hope in the next future also to other subcutaneous drugs, some tools are starting to be explored. And I think that in the next future, thanks to these tools like OBI or body injector, maybe we can drive a lot of patients at home and maybe we can really make myeloma a chronic disease in which the patients come only rarely to the hospital. And this will be in some way a new era for not only the patient but also for the optimization of staff of the hospitals and also for caregivers. I think that OBI is a great revolution, is a great game changer in the therapeutic panorama of multiple myeloma and I think that the best has to come in the future with positioning and potentially new opportunities that decentralize the patient also in their domestic setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.